Tezepelumab (AMG‐157/MEDI9929) is a first‐in‐class human IgG2λ monoclonal antibody that inhibits the action of TSLP, which has been tested in a recent clinical trial, and the results revealed that AD patients have improved symptoms over placebo.265, 266. This evidence concerns the gene TSLP and Alzheimer disease.